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ABSTRACT
Background and aims Cost-effectiveness studies in randomized clinical trials have shown that tobacco cessation phar-
macotherapy is among the most cost-effective of health-care interventions. Clinical trial eligibility criteria and treatment
protocols may not be followed in actual practice. This study aimed to determinewhether tobacco cessation pharmacother-
apy is cost-effective in real-world settings.Design A retrospective analysis of costs and outcomes. Setting Hospitals and
clinics of the US Veterans Health Administration, USA. Participants A total of 589862 US veterans who screened
positive for tobacco use in 2011. Intervention and comparator Tobacco users who initiated smoking cessation phar-
macotherapy in the 6 months after screening were compared with those who did not use pharmacotherapy in this period.
Pharmacotherapy included nicotine replacement therapy, bupropion (if prescribed at 300 mg per day or specifically for
tobacco cessation) or varenicline. Measures Effectiveness was determined from responses to a subsequent tobacco
screening conducted between 7 and 18 months after the treatment observation period. Cost of medications and prescrib-
ing health-care encounters was determined for the period between initial and follow-up tobacco use screening. Multivar-
iate fixed-effects regression was used to assess the effect of initial treatment status on cost and outcome while controlling
for differences in case-mix with propensity weighting to adjust for confounding by indication. Findings Thirteen per cent
of participants received tobacco cessation pharmacotherapy within 6 months of initial screening. After an average of an
additional 218.1 days’ follow-up, those who initially received pharmacotherapy incurred $143.79 in additional treatment
cost and had a 3.1% absolute increase in tobacco quit rates compared with those who were not initially treated. This
represents an incremental cost-effectiveness ratio of $4705 per quit. The upper limit of the 99.9% confidence region
was $5600 per quit. Without propensity adjustment, the cost-effectiveness ratio was $7144 per quit, with the upper
limit of the 99.9% confidence region $9500/quit. Conclusions Tobacco cessation pharmacotherapy provided by the
US Veterans Health Administration in 2011/12 was cost-effective in this real-world setting, with an incremental
cost-effectiveness ratio of $4705 per quit.
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INTRODUCTION
Randomized clinical trials (RCTs) indicate that tobacco
use can be successfully treated using tobacco cessation
pharmacotherapy, including nicotine replacement
therapy (NRT), bupropion and varenicline [1]. However,
the efficacy demonstrated in trials does not necessarily
translate to equivalent effectiveness in actual practice
[2], because treatment is extended to patients who
may not meet strict eligibility criteria, including
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those with co-occurring substance use disorders and
serious mental illness. Furthermore, treatment may not
follow the protocol used in trials, including adjuvant
counseling [3].
While some studies in real-world settings have found to-
bacco pharmacotherapies to be effective [4,5], especially
when accompanied by behavioral support or brief advice
[6], other studies have found that increased use of NRT
has not improved long-term quit [7] or relapse rates [8].
Such observational studies have been limited by small
sample sizes, lack of covariates and concerns over study
design, including the non-random nature of treatment
assignment, which may result in selection bias [9–11].
Cost-effectiveness studies based on cost and outcomes
observed in clinical trials have determined that tobacco
cessation pharmacotherapy is among the most cost-
effective health-care interventions [12–14]. Real-world
cost-effectiveness may differ. As treatment is expanded to
reach smokers who are harder to treat, more resources
are required to achieve a successful quit, and cost-
effectiveness can be expected to decline [15].
The United States Veterans Health Administration
(VHA) expanded its tobacco cessation program in 2004,
increasing the percentage of tobacco using patients who
received a pharmacotherapy from 13.8% in 2004 to
26.8% in 2008 [16]. In a recent study published in Tobacco
Control, we studied 589862 veterans who screened
positive for tobacco use at VHA in 2011 and found that
(controlling for case-mix and confounding by indication)
quit rates for those who received pharmacotherapy were
significantly higher than that in those who were not
treated, 19.8 versus 16.7% (P < 0.001) [17]. In the cur-
rent paper, we test the hypothesis that tobacco cessation
pharmacotherapy is cost-effective in the real-world setting
of VHA.
METHODS
This retrospective cohort study was assembled using data
extracted from the Electronic Medical Record (EMR) of
VHA, including information on tobacco status recorded
in response to clinical reminders [18], dispensed prescrip-
tions for tobacco cessation pharmacotherapy, patient
demographics and diagnoses assigned in in-patient stays
and out-patient visits. The study protocol was approved
by the Institutional Review Boards (IRBs) at the AnnArbor
and VA Palo Alto VHAs. Approval was granted for retro-
spective use of data from the date of the IRB submission,
30 September 2013.
Sample
The participants included VHA out-patients identified as
using tobacco in routine screening conducted in the year
that ended on 30 September 2011. The treatment observa-
tion period was the 6 months after initial screening. Out-
comes were as assessed in the last tobacco use screening
that occurred within 7 and 18months after the end of this
treatment observation period.
To focus the evaluation on the initiation of new epi-
sodes of tobacco cessation pharmacotherapy, patients were
excluded if they had used pharmacotherapy in the
12months prior to the index date [19]. Also excluded were
those whose EMR had missing data on race, follow-up to-
bacco use or other covariates needed to adjust for the pro-
pensity to receive pharmacotherapy. Of 838309 tobacco
users without pharmacotherapy in the prior year, 53218
(6.3%) were excluded because of missing data (chiefly race
or ethnicity) and 195229 (23.3%) were excluded because
there was no follow-up tobacco use assessment. Complete
details on the cohort are reported in an earlier paper on
pharmacotherapy effectiveness [17].
Measures
Treatment
Participants were deemed treated if NRT, bupropion or
varenicline was released to the veteran either in person
or by mail during the 6-month period following the initial
screening. As bupropion can be prescribed for purposes
other than tobacco cessation, bupropion was regarded as
tobacco cessation pharmacotherapy only if the prescription
was labeled as being for tobacco cessation or if it was pre-
scribed at a dose of 300 mg per day, the dosage approved
by the Food and Drug Administration for tobacco cessa-
tion. Lower dosages of bupropion, typically used for depres-
sion, but not for tobacco treatment, were not considered
cessation pharmacotherapy.
Outcomes
Outcomes were based on the results of tobacco use
screening that was 7–12 months after the initial
assessment. A 7–12 month follow-up period is
recommended for the evaluation of tobacco cessation in-
terventions [20–22]. Screenings are not scheduled, but
provided during routine visits according to VHA policy
to provide tobacco users with annual screening. Out-
comes were determined using the results of the last
tobacco use screening that occurred between 7 and
18 months after the index date. Because preference rated
health-related quality of life, the information needed to
express outcomes in terms of quality-adjusted life-years
(the standard outcome used for cost-effectiveness analy-
sis) is not routinely gathered and was not available in
the EMR, cost-effectiveness was determined as the cost
per quit, a measure reported by most economic evalua-
tions of randomized trials.
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Case-mix
Case-mix measures were patient characteristics available
in the EMR that are known to affect quit rates, including
age, sex, race and ethnicity, as well as psychiatric, sub-
stance abuse and medical comorbidities [23–28] assigned
in encounters in the 12 months prior to the initial tobacco
use screening. Medical comorbidities were defined using
the most recent update of the method developed by
Elixhauser [23].
Cost
Cost and quantity of tobacco cessation pharmacotherapy
were determined for the treatment period (from initial
screening until 6 months later) and for the follow-up
period (from the beginning of the seventh month until
the date of the follow-up tobacco use assessment). Cost
was assessed from the VHA perspective, which is both the
health-care provider and the health-care sponsor. The
direct cost of medication was the VHA acquisition cost as
recorded in prescription records. Implausibly extreme
values for the unit cost of a dispensed prescription of
pharmacotherapy were corrected using the median unit
cost of the medication for records with costs below the
10th or above the 90th percentile (or for NRT nasal spray,
because of the increased variability in this small number of
records, below the 25th or above the 75th percentile).
Pharmacy costs other than medication (including
supplies, labor costs and overheads) were determined by
analysis of the VHA managerial cost accounting system.
These non-medication costs were included by adding
66% to the direct medication cost of NRT, 56% to the
medication cost of bupropion and 48% to the medication
cost of varenicline.
Because the VHA provides tobacco cessation pharma-
cotherapy only by prescription, the cost of patient evalua-
tion and pharmacotherapy prescription was included. A
cost of $27 was assigned for new prescriptions. This was
the 2013 Medicare reimbursement for intensive tobacco
use cessation counseling during an office-based visit (CPT
code 99407). No additional evaluation cost was assigned
for a second prescription filled on the same day, or for
prescription refills. As both treated and untreated
individuals had an initial and follow-up tobacco use
assessment, cost for these assessments was not included
as it would not affect estimates of the incremental cost of
treatment. Tobacco cessation counseling was not
consistently identifiable in VA utilization data, and its cost
was not included.
Current evidence is contradictory concerning whether
tobacco use cessation is associated with increased or
decreased subsequent health care utilization and cost
[29–31]. Moreover, human studies only allowed retro-
spective data collection from the date of approval. For
these reasons, a short-term horizon was adopted with
the assumption that neither cessation nor continuation
affects health-care cost. Costs were adjusted to 2013 US
$ using the Consumer Price Index for urban consumers
for all items.
Statistical analysis
The effect of pharmacotherapy treatment was estimated
using generalized linear regression models, with the
independent variable an indicator representing receipt of
treatment in the initial 6 months of observation. A
logistic regression was used for discrete-dependent vari-
ables (quit, use of pharmacotherapy), negative binomial
regression for count-dependent variables (quantity of
pharmacotherapy received) and gamma regression for
cost-dependent variables.
Fixed-effects regression models were estimated. These
fixed-effects were indicator variables for the facility where
the initial tobacco use assessment took place. Theywere in-
cluded to control for unmeasured facility-level differences
in the use of pharmacotherapy and location-specific differ-
ences affecting tobacco use, such as tobacco tax rates and
smoking regulations.
Propensity weighting
Because participants were not randomly assigned to treat-
ment, propensity weightingwas used to adjust for selection
bias. Observations were weighted by the inverse of the
probability of receiving the treatment the subject actually
received during the 6-month treatment period [32]. The
inverse probability of treatment weight (IPTW) increases
the influence of observations with an unlikely assignment
(e.g. veterans with characteristics suggesting they would
receive treatment who were not treated) and decreases
the influence of observations with a probable assignment
(e.g. veterans with characteristics suggesting they would
receive treatment who were treated). This correction is
designed to approximate the randomized assignment of
treatment in a RCT. It is comparable to the weights that
are used to adjust surveys so that they represent the popu-
lation being sampled.
IPTWs were estimated from a multivariable logistic
regression model that used pharmacotherapy initiation as
the dependent variable and patient demographics and
diagnoses as independent variables [33]. To provide the
best possible predicted propensity, the model included
diagnosis indicator variables, polynomial terms for age,
counts of psychiatric and medical conditions and
interaction terms of age by each psychiatric and medical
diagnosis. The propensity model also included facilities as
fixed-effects.
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Plots of propensity to receive treatment by treatment
groups were evaluated, and it was determined that overlap
was sufficient to justify adjustment by IPTW. Standardized
mean difference in covariates between treatment groups of
less than 0.10, a frequently used criterion for adequacy of
covariate balancing, was used as the threshold to evaluate
if adjustment for baseline differences was adequate
[34,35]. Unadjusted analysis was contrasted to the IPTW
adjusted findings to provide information on the effect of
adjustment.
Cost-effectiveness analysis
The incremental cost-effectiveness ratio (ICER) was esti-
mated as the incremental cost (difference in propensity
weighted mean cost) per additional quit (difference in
propensity weighted proportion that quit) during the short
term, the interval between screenings (the 6 months of
the medication observation period plus an additional
7–18 months until the follow-up screening).
Bootstrap sampling was used to estimate the uncer-
tainty of the ICER. Each replicate included 589862
observations obtained by selecting randomly with replace-
ment from study data. The probability of selection was
proportional to the observation’s IPTW. The criterion for
statistical significance was a probability of less than
0.001 for a type I statistical error. The upper limit of the
99.9% confidence region of the ICER was found in 1000
bootstrap replicates.
RESULTS
There were 589862 individuals who met study inclusion
criteria. Table 1 compares the 76739 (13.0%) initially
treated (those who received pharmacotherapy within
6 months of the initial screening for tobacco use) to the
513123 (87.0%) tobacco users who were not initially
treated. Those initially treated had more psychiatric co-
morbidities, except for schizophrenia, which was more
common among those not initially treated. Those initially
treated had fewer medical comorbidities, but more chronic
obstructive pulmonary disease and cirrhosis than those not
initially treated.
Table 1 also shows the standardized differences in the
mean values of covariates between groups defined by initial
treatment status. Unweighted differences exceeded 0.10
standard deviations for five of the 44 baseline characteris-
tics, suggesting some important differences between the
groups. After IPTW adjustment, the standardized differ-
ence of all covariates had an absolute value of less than
0.10. The use of propensity adjustment was supported by
the substantial overlap in predicted probabilities between
treatment groups: range = 0.0047–0.7734 for those ini-
tially treated and 0.0010–0.7584 for those not initially
treated. Because of this overlap, and because standardized
differences were reduced by adjustment, trimming of obser-
vations with extreme probability values was deemed
unnecessary.
Table 2 describes the propensity-adjusted use of tobacco
cessation pharmacotherapy during the initial 6-month
treatment observation period in those initially treated (see
Supplemental Table 1 for unadjusted results). NRT was re-
ceived by 77.7%, bupropion was received by 26.7% and
only 5.6% received varenicline. Some participants had
more than one treatment, and the total exceeds 100%.
On average, the cost of treatment during the initial period
was $120.51, including $81.58 medication cost and
$38.93 prescribing cost.
The propensity-adjusted use and cost of tobacco cessa-
tion pharmacotherapy in the follow-up period is presented
by treatment group in Table 3 (see Supplemental Table 2
for unadjusted results). During the follow-up period,
28.2% of those initially treated received pharmacotherapy;
however (as might also occur in an RCT), some (8.2%) of
those not initially treated received pharmacotherapy in
the follow-up period (P < 0.001). Tobacco pharmacother-
apy cost during the follow-up period was greater in those
initially treated versus those not initially treated ($32.70
versus $9.42, P < 0.001). The average length of the
follow-up period was slightly longer among those initially
treated (220.6 days versus 218.1 days, P < 0.001).
Table 4 compares the cost and outcomes by treatment
group and reports the ICER. The average cost among those
initially treated was $143.79 greater than those not
initially treated ($153.21 versus $9.42, P < 0.001). The
absolute difference in percentage quit was 3.06% more in
the initially treated group (19.73 versus 16.67%,
P < 0.001). The ICER was $4705 per quit
($4705 = $143.79/0.0306). Bootstrap evaluation of
study data found a standard error of $233/quit. Uncer-
tainty of the estimate of cost per quit was also plotted on
a cost-effectiveness acceptability curve (Fig. 1). The upper
limit of the 99.9% confidence region of the ICER was
$5600/quit (i.e. 99.9% of 1000 bootstrap replicates had
an ICER below this threshold).
Cost-effectiveness was also determined without propen-
sity adjustment (also shown in Table 4; with details of un-
adjusted analysis in the Supporting Information, Tables S1
and S2). Bootstrap sampling with equal probability and
with replacement found incremental cost of pharmaco-
therapy was $147.98 ($157.24 in initially treated versus
$9.26 in not initially treated) and the incremental effec-
tiveness was 2.07% additional quits (18.80% quit in ini-
tially treated versus 16.73% quit in not initially treated).
The ICER was $7144 per quit, (7144 = 147.98/.0207)
with a standard error of $514/quit. The upper limit of
the 99.9% confidence region of the unadjusted ICER was
$9500/quit.
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Table 1 Percentage of baseline patient characteristics by tobacco cessation pharmacotherapy treatment group and standardized weighted
and unweighted differences (n = 589862).
Characteristics
Initially treated
(n = 76739)
Not initially treated
(n = 513 123) P-valuea
Standardized difference,
unweightedb
Standardized
difference, weightedc
Psychiatric diagnosis
Depression 32.8 25.2 < 0.001 0.168 0.028
Bipolar disorder 5.3 3.8 < 0.001 0.072 0.003
Schizophrenia 3.2 4.0 < 0.001 0.044 0.037
Post-traumatic stress
disorder
18.7 15.1 < 0.001 0.095 0.005
Alcohol 18.6 15.8 < 0.001 0.076 0.005
Other substance use
disorders
13.3 10.2 < 0.001 0.097 0.001
Other anxiety 13.0 10.5 < 0.001 0.079 0.002
Other psychosis 1.6 1.6 0.884 0.001 0.014
Medical comorbidity
Congestive heart failure 2.9 3.5 < 0.001 0.035 0.003
Cardiac arrhythmia 5.5 6.9 < 0.001 0.060 0.004
Valvular disease 1.2 1.6 < 0.001 0.032 0.000
Pulmonary circulation
disorders
0.6 0.6 0.251 0.004 0.002
Peripheral vascular
disorders
6.7 7.1 0.001 0.013 0.014
Hypertension
uncomplicated
48.7 55.7 < 0.001 0.139 0.016
Hypertension
complicated
0.7 1.2 < 0.001 0.045 0.005
Paralysis 0.6 0.7 < 0.001 0.014 0.004
Other neurological
disorders
2.8 3.4 < 0.001 0.033 0.018
Chronic obstructive
pulmonary disease
20.6 18.7 < 0.001 0.047 0.045
Diabetes uncomplicated 18.1 21.9 < 0.001 0.096 0.012
Diabetes complicated 4.2 5.2 < 0.001 0.045 0.002
Hypothyroidism 4.0 4.8 < 0.001 0.037 0.010
Renal failure 2.4 3.7 < 0.001 0.079 0.010
Liver disease 4.4 4.1 < 0.001 0.015 0.001
Peptic ulcer disease
excluding bleeding
0.9 1.0 0.001 0.013 0.001
AIDS/HIV 0.7 0.7 0.993 0.000 0.002
Lymphoma 0.4 0.4 0.016 0.010 0.001
Metastatic cancer 0.2 0.3 0.018 0.009 0.001
Solid tumor without
metastasis
5.5 6.4 < 0.001 0.040 0.004
Rheumatoid arthritis 1.5 1.6 0.134 0.006 0.001
Coagulopathy 0.8 1.0 < 0.001 0.027 0.006
Obesity 14.7 14.8 0.492 0.003 0.005
Weight loss 2.2 2.2 0.941 0.000 0.008
Fluid and electrolyte
disorders
2.6 3.2 < 0.001 0.031 0.006
Blood loss anemia 0.1 0.1 0.949 0.000 0.002
Deficiency anemia 1.3 1.7 < 0.001 0.035 0.007
Age group (years) < 0.001
18–44 20.3 14.9 0.142 0.003
45–54 22.6 18.1 0.112 0.002
55–64 41.7 41.0 0.014 0.003
65+ 15.4 25.9 0.263 0.005
Male 92.2 94.2 < 0.001 0.081 0.002
(Continues)
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DISCUSSION
This study of real-world practice found that veterans who
used tobacco and initiated a new episode of cessation phar-
macotherapy incurred $143.79 in additional cost, with a
3.1% greater absolute rate of quitting tobacco. The
resulting incremental cost-effectiveness ratio of $4705
per quit was similar to that found by RCTs [36,37]. For ex-
ample, Ronckers standardized the cost-effectiveness ratios
found by 23 economic evaluations of cessation studies
and found the interquartile range of these estimates was
$2160–5180 per quit (all cost-effectiveness estimates from
the literature in this discussion were converted to 2013 US
$ to be comparable to the findings of this study). Moreover,
the interquartile range of 15 studies reviewed by Shearer
was $2080–4030 per quit. This suggests that tobacco ces-
sation pharmacotherapy in a real-world setting delivers
similar value, as has been demonstrated in RCTs.
Previous estimates of the cost-effectiveness of tobacco
cessation pharmacotherapy have relied on data fromRCTs,
many of which excluded potential participants with
substance use disorders or serious mental illness. As these
conditions are associated with lower treatment success
and higher relapse rates [38,39], it is possible that existing
cost-effectiveness estimates are overly optimistic. This is an
especially important concern because those with these
conditions are more likely to use tobacco [38,40,41]. This
study includedmany tobacco users with substance use dis-
orders and serious mental illness and found the ICER to be
comparable to other RCTs, suggesting that this concern
Table 1. (Continued)
Characteristics
Initially treated
(n = 76739)
Not initially treated
(n = 513 123) P-valuea
Standardized difference,
unweightedb
Standardized
difference, weightedc
Race 0.002
White 76.8 77.4 0.014 0.006
Black 19.5 19.0 0.012 0.005
Other 3.7 3.6 0.006 0.003
Hispanic 3.5 3.5 0.754 0.001 0.002
aFrom standard χ
2
test comparing treated and not treated group of the unweighted cohort (prior to propensity weighting). bStandardized difference is the dif-
ference in means divided by the square root of the pooled variance. cWeighted standardized differences are based on inverse probability of treatment from a
multivariable logistic regression of pharmacotherapy initiation with independent variables age, gender, race, Hispanic ethnicity, eight psychiatric/substance
use disorder diagnoses, 27 medical diagnoses, facility fixed-effects, count of psychiatric/substance use diagnoses, count of medical conditions, age-squared,
age-cubed, interactions of age with each psychiatric and medical diagnosis.
Table 2 Propensity-adjusted tobacco cessation pharmacotherapy utilization and cost in initial treatment period among those treated for
tobacco use (n = 76 739).
Type of
pharmacotherapy
Percenage receiving different types of
pharmacotherapy Unit
Mean quantity of
pharmacotherapy
Mean cost of pharmacotherapy
(US 2013 dollars)
NRT patch 58.7 Days’
supply
28.6 44.37
NRT gum 18.4 Pieces 39.7 9.79
NRT lozenge 11.7 Pieces 21.4 10.69
NRT inhaler 0.08 Cartridges 0.22 0.23
NRT nasal spray 0.017 10-ml
bottles
0.0011 0.05
Any type of NRT 77.7 NA NA 65.13
Bupropion 26.7 Days’
supply
19.7 6.98
Varenicline 5.6 Days’
supply
2.5 9.47
Any type of
pharmacotherapy
100.0 81.58
Prescription visits 38.93
Total cost, initial period 120.51
NA = not applicable; NRT = nicotine replacement therapy.
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may not be warranted. Further study of cost-effectiveness
of specific pharmacotherapies in different patient sub-
groups is needed.
This study did not express outcomes in terms of life-
years or quality-adjusted life-years or consider long-term
relapse or quit rates. Models of cost-effectiveness of tobacco
cessation pharmacotherapy have found that, during the
long term, successful quitters gain approximately 2 years
of life relative to those who did not quit [42]. If those who
initially received pharmacotherapy in this study realized a
similar benefit, cessation pharmacotherapy as practiced
by VHA would be estimated to have an ICER of about
$2350 per life-year. This is consistent with the cost-
effectiveness of tobacco cessation treatments found in other
Table 3 Propensity-adjusted tobacco cessation pharmacotherapy utilization and cost in follow-up period, by treatment group.
Percentage of individuals Mean quantity of pharmacotherapy
Mean cost of pharmacotherapy
(US 2011 dollars)
Initially
treated
Not initially
treated
Initially
treated
Not initially
treated
Initially
treated
Not initially
treated
NRT patch (days’ supply) 11.4% 4.8%* 5.45 2.29* 7.82 3.29*
NRT gum (pieces) 4.9% 1.6%* 12.08 3.25* 2.91 0.78*
NRT lozenge (pieces) 3.7% 1.1%* 7.86 1.84* 3.86 0.90*
NRT inhaler (cartridges) 0.038% 0.009%* 0.11 0.03† 0.11 0.03*
NRT nasal spray (10-ml bottles) 0.012% 0.002%* 0.0017 0.0001* 0.09 0.005*
Any type of NRT 17.3% 6.4%* 14.78 5.01*
Bupropion (days’ supply) 12.3% 2.2%* 13.41 1.76* 4.48 0.56*
Varenicline (days’ supply) 1.7% 0.3%* 0.83 0.15* 3.19 0.59*
Any type of pharmacotherapy 28.2% 8.2%* 22.45 6.16*
Prescription visits 10.25 3.26*
Total 32.70 9.42*
Initially treated with pharmacotherapy (n = 76 739) versus not initially treated with pharmacotherapy (n = 513 123). *P< 0.001; †P< 0.05. Mean follow-
up period 220.6 days initially treated versus 218.1 days not initially treated, P < 0 0.001. NRT = nicotine replacement therapy.
Table 4 Tobacco cessation pharmacotherapy cost, outcomes and cost-effectiveness by treatment group (propensity-adjusted and
unadjusted results).
Initially treated with
pharmacotherapy
Not initially treated with
pharmacotherapy Difference P-value
Estimates with propensity weighting adjustment for selection bias
Initial period cost 120.51 0.00 120.51 –
Follow-up period cost 32.70 9.42 23.28 < 0.001
Total cost 153.21 9.42 143.79 < 0.001
Percentage quit tobacco use
at follow-up
19.73% 16.67% 3.06% < 0.001
Incremental cost effectiveness
ratio (cost per quit)
Mean $4705/quit < 0.001
Standard error ± $232.91/
quit
Upper limit of 99% confidence region $5600/quit
Raw estimates (no propensity adjustment)
Initial period cost 122.58 0.00 122.58 –
Follow-up period cost 34.66 9.26 25.39 < 0.001
Total cost 157.24 9.26 147.98 < 0.001
Percent quit tobacco use
at follow-up
18.80% 16.73% 2.07% < 0.001
Incremental cost effectiveness
ratio (cost per quit)
Mean $7144/quit < 0.001
Standard error ± $513.89/
quit
Upper limit of 99% confidence region $9500/quit
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studies, which report ICERs that range from $1210 to
$4546 per life-year gained [42]. These values are quite
low compared to other health-care interventions, making
tobacco cessation among the most cost-effective of health
services [15].
The size of the effect of pharmacotherapy was small, in
part because the quit rate in the group not initially treated
was 16.7%, higher than the 5–6% annual quit rates ob-
served in other populations [43,44]. This is consistent with
some clinical trials that have noted high quit rates in their
control groups [8,45]. Although the effect size found in this
study was small, it was sufficiently large relative to the cost
of the intervention to be considered cost-effective.
The study did not include the cost of behavioral
counseling beyond that provided by the provider during
the visit in which a new tobacco cessation pharmacother-
apy was prescribed. Other tobacco cessation counseling
cannot be easily identified in the EMR, as it is often pro-
vided as part of a visit at which other services are provided.
This study did not include the cost of this additional
counseling, possibly understating the cost of pharmaco-
therapy. Participants who did not receive pharmacother-
apy were also screened for tobacco use and were likely to
have received at least brief advice to quit. Such brief advice
and the receipt of pharmacotherapy in the follow-up period
may explain the high quit rate in the group that was not
initially treated.
It was assumed that higher doses of bupropion were
prescribed for smoking cessation, but these higher doses
may have been prescribed for depression. Approximately
6% of the potential cohort was excluded because data for
race were missing. Sensitivity analyses involving alterna-
tive criteria for defining bupropion for tobacco cessation,
and including observations with missing data on race
(and excluding race from the covariates), showed little
effect on the estimate of treatment effectiveness [17]. These
sensitivity analyses were not repeated for this cost-
effectiveness study.
Cost-effectiveness analysis without adjustment by
IPTW weights results in a cost-effectiveness ratio that is
higher than when propensity adjustment is used. This dif-
ference suggests that tobacco users with a lower chance
of quitting are more likely to receive pharmacotherapy; ad-
justment for this imbalance improves cost-effectiveness, re-
ducing the incremental cost effectiveness ratio from
$7144/quit to $4407/quit. Even without propensity ad-
justment, pharmacotherapy cost less than $9500 per quit
in 99.9% of the bootstrap replications.
This evaluation of treatment as actually practiced
comes with the risk of bias from non-random assignment.
Even though we used best practices for adjusting for
confounding by indication, re-weighting observations to
approximate the result of random assignment, this method
relies on the untestable assumption that the observed
covariates fully account for propensity to receive treat-
ment. However, the strength of real-world observational
studies such as this one is the generalizability that is not
realized in RCTs.
CONCLUSION
This observational study used propensity adjustment to
control for non-random treatment assignment and found
that tobacco cessation pharmacotherapy as currently
provided by VHA has an incremental cost-effectiveness
ratio of $4705 per quit. This finding adds to the evidence
that these medications deliver sufficient value to justify
their cost.
Figure 1 Cost-effectiveness acceptability curve. The upper limit of the 99.9% confidence region of the incremental cost-effectiveness ratio (ICER)
was $5600/quit (that is, 99.9% of 1000 bootstrap replicates had an ICER below this threshold). [Colour figure can be viewed at wileyonlinelibrary.com]
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